Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blocking Formation of Scar Tissue Increases Susceptibility of Pancreatic Cancer to Immunotherapy

By LabMedica International staff writers
Posted on 13 Jul 2016
Cancer researchers have shown that treatment with a focal adhesion kinase (FAK) inhibitor rendered pancreatic cancer tumors susceptible to immunotherapy in a mouse model of the disease.

To date immunotherapy has achieved only limited clinical benefits in patients with pancreatic ductal adenocarcinoma (PDAC). More...
This may be a result of the presence of a uniquely immunosuppressive tumor microenvironment (TME) characterized by a high number of tumor-associated immunosuppressive cells and a scar-like stroma that surrounds the tumor and functions as a barrier to T-cell infiltration.

Investigators at the Washington University School of Medicine (St. Louis, MO, USA) reported in the July 4, 2016, online edition of the journal Nature Medicine that hyperactivated focal adhesion kinase (FAK) activity was present in neoplastic PDAC cells and acted as an important regulator of the fibrotic and immunosuppressive TME. FAK activity was elevated in human PDAC tissues and correlated with high levels of fibrosis and poor cytotoxic T-cell infiltration.

To block formation of the scar tissue preventing T-cell infiltration, the investigators treated a pancreatic cancer mouse model with the selective FAK inhibitor VS-4718. They found that this treatment substantially limited tumor progression, resulting in a doubling of survival time in the mouse model of human PDAC. This delay in tumor progression was associated with markedly reduced tumor fibrosis and decreased numbers of tumor-infiltrating immunosuppressive cells.

The investigators also found that FAK inhibition rendered the previously unresponsive mouse model responsive to T-cell immunotherapy and PD-1 antagonistic chemotherapeutic agents. A three-drug combination of FAK inhibitor, immune therapy, and chemotherapy more than tripled survival times in some mice.

"Pancreatic tumors are notoriously unresponsive to both conventional chemotherapy and newer forms of immunotherapeutics," said senior author Dr. David G. DeNardo, assistant professor of medicine at the Washington University School of Medicine. "We suspect that the fibrous environment of the tumor that is typical of pancreatic cancer may be responsible for the poor response to immune therapies that have been effective in other types of cancer."

"Proteins called focal adhesion kinases are known to be involved in the formation of fibrous tissue in many diseases, not just cancer," said Dr. DeNardo. "So we hypothesized that blocking this pathway might diminish fibrosis and immunosuppression in pancreatic cancer."

Related Links:
Washington University School of Medicine



Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.